Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity
Duncan Howie, … , Alexander G. Betz, Herman Waldmann
Duncan Howie, … , Alexander G. Betz, Herman Waldmann
Published February 9, 2017
Citation Information: JCI Insight. 2017;2(3):e89160. https://doi.org/10.1172/jci.insight.89160.
View: Text | PDF
Research Article Immunology Metabolism

Foxp3 drives oxidative phosphorylation and protection from lipotoxicity

  • Text
  • PDF
Abstract

Tregs can adopt a catabolic metabolic program with increased capacity for fatty acid oxidation–fueled oxidative phosphorylation (OXPHOS). It is unclear why this form of metabolism is favored in Tregs and, more specifically, whether this program represents an adaptation to the environment and developmental cues or is “hardwired” by Foxp3. Here we show, using metabolic analysis and an unbiased mass spectroscopy–based proteomics approach, that Foxp3 is both necessary and sufficient to program Treg-increased respiratory capacity and Tregs’ increased ability to utilize fatty acids to fuel oxidative phosphorylation. Foxp3 drives upregulation of components of all the electron transport complexes, increasing their activity and ATP generation by oxidative phosphorylation. Increased fatty acid β-oxidation also results in selective protection of Foxp3+ cells from fatty acid–induced cell death. This observation may provide novel targets for modulating Treg function or selection therapeutically.

Authors

Duncan Howie, Stephen Paul Cobbold, Elizabeth Adams, Annemieke Ten Bokum, Andra Stefania Necula, Wei Zhang, Honglei Huang, David J. Roberts, Benjamin Thomas, Svenja S. Hester, David J. Vaux, Alexander G. Betz, Herman Waldmann

×

Figure 4

Foxp3 exerts transcriptional control on multiple mitochondrial genes.

Options: View larger image (or click on image) Download as PowerPoint
Foxp3 exerts transcriptional control on multiple mitochondrial genes.
Co...
Comparison of Foxp3 positive and negative T cells polarized under iTreg conditions and EL4 cells expressing conditional Foxp3 treated with and without tamoxifen by qPCR array. Data for A–C represent the mean of qPCR performed separately on 3 biological replicates, then pooled. (A) Comparison of the fold change of all the glycolytic gene set transcripts with the mitochondrial component gene set transcripts in Foxp3 positive and negative iTreg by 2-way ANOVA. Boxes span 25th to 75th percentiles, whiskers represent minimum and maximum values, and horizontal line shows median. “X” marks mean, ***P < 0.005. (B) Comparison of the fold change of all the glycolytic gene set transcripts with the mitochondrial component gene set transcripts in nuclear Foxp3+ versus cytoplasmic Foxp3+ EL4 T cells by 2-way ANOVA. Boxes span 25th to 75th percentiles, whiskers represent minimum and maximum values, and horizontal line shows median. “X” marks mean, ***P < 0.005. (C) Heat map of qPCR array data. Glycolysis- and mitochondrial-associated genes, as well as their fold changes, are listed. EL4 fold change indicates the ratio of 4’HT to non–4’HT-treated cells. iTreg fold change indicates the ratio of CD2+RAG–/–Marilyn.Foxp3hCD2 to CD2–cells. Red indicates transcripts with a ratio >1.00, and green indicates transcripts with a ratio <1.00. tam, tamoxifen.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts